Sola Diagnostics

About:

Cancer prevention by epigenetic-based risk prediction

Website: http://www.sola-diagnostics.com

Top Investors: FPS-Holding

Description:

Home of the WID®-Test - Sola commits to supporting the translation of promising science in cancer prevention by epigenetic-based risk prediction into marketable products to benefit patients and society.

Total Funding Amount:

1.99M EUR

Headquarters Location:

Innsbruck, Tirol, Austria

Founded Date:

2020-05-29

Contact Email:

info(AT)sola-diagnostics.com

Founders:

Peter Key

Number of Employees:

1-10

Last Funding Date:

2024-06-24

IPO Status:

Private

Industries: